Trademark: 97405280
Word
ADPL
Status
Registered
Status Code
700
Status Date
Tuesday, September 5, 2023
Serial Number
97405280
Registration Number
7154375
Registration Date
Tuesday, September 5, 2023
Mark Type
4000
Filing Date
Wednesday, May 11, 2022
Published for Opposition
Tuesday, June 20, 2023

Trademark Owner History
Mercury Pharma Group Limited - Original Registrant

Classifications
5 A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations

Trademark Events
Sep 5, 2023
Notice Of Registration Confirmation Emailed
Sep 5, 2023
Registered-Principal Register
Jun 20, 2023
Official Gazette Publication Confirmation E-Mailed
Jun 20, 2023
Published For Opposition
May 31, 2023
Notification Of Notice Of Publication E-Mailed
May 15, 2023
Law Office Publication Review Completed
May 8, 2023
Approved For Pub - Principal Register
May 4, 2023
Teas/Email Correspondence Entered
May 4, 2023
Correspondence Received In Law Office
May 4, 2023
Assigned To Lie
Feb 2, 2023
Teas Response To Suspension Inquiry Received
Jan 24, 2023
Notification Of Letter Of Suspension E-Mailed
Jan 24, 2023
Letter Of Suspension E-Mailed
Jan 24, 2023
Suspension Letter Written
Jan 24, 2023
Examiner's Amendment Entered
Jan 24, 2023
Notification Of Examiners Amendment E-Mailed
Jan 24, 2023
Examiners Amendment E-Mailed
Jan 24, 2023
Examiners Amendment -Written
Jan 18, 2023
Assigned To Examiner
May 17, 2022
New Application Office Supplied Data Entered
May 14, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24